Skip to main content
. 2019 Mar 18;7(3):48. doi: 10.3390/medsci7030048

Figure 1.

Figure 1

Kaplan–Meier plot of progression-free survival of the 123 patients with soft tissue and bone sarcoma treated with pazopanib. Two patients had not progressed and were censored (one with low-grade fibromyxoid sarcoma and one with synovial sarcoma).